P53 mutations in colorectal cancer from Northern Iran: Relationships with site of tumor origin, microsatellite instability and K-ras mutations

Journal of Cellular Physiology

Volumn 216, Issue 2, 2008, Pages 543-550

  Mahdavinia, Mahboobeh ^a,b   Bishehsari, Faraz ^a,b   Verginelli, Fabio ^a   Cumashi, Albana ^a   Lattanzio, Rossano ^a   Sotoudeh, Masoud ^b,c   Ansari, Reza ^b   Semeraro, Daniela ^d   Hormazdi, Mahshid ^d   Fakheri, Hafez ^e   Rakhshani, Naser ^b   De Lellis, Laura ^a   Curia, Maria Cristina ^a   Cama, Alessandro ^a   Piantelli, Mauro ^a   Malekzadeh, Reza ^b   Iacobelli, Stefano ^a   Mariani Costantini, Renato ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Mehr Hospital Iran   (Iran)

^e MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; PROTEIN P53;

ADULT; AGED; ARTICLE; ASCENDING COLON; CANCER RISK; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CODON; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; CPG ISLAND; DESCENDING COLON; EXON; FEMALE; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IRAN; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MUCINOUS CARCINOMA; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, RAS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IRAN; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 46049107947     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21428     Document Type: Article

References (47)

1. Ansari R, Mahdavinia M, Sadjadi A, Nouraie M, Kamangar F, Bishehsari F, Fakheri H, Semnani S, Arshi S, Zahedi MJ, Darvish-Moghadam S, Mansour-Ghanaei F, Mosavi A, Malekzadeh R. 2006. Incidence and age distribution of colorectal cancer in Iran: Results of a population-based cancer registry. Cancer Lett 240:143-147.
2. Arnold CN, Goel A, Blum HE, Boland CR. 2005. Molecular pathogenesis of colorectal cancer: Implications for molecular diagnosis. Cancer 104:2035-2047.
3. Bazan V, Migliavacca M, Tubiolo C, Macaluso M, Zanna I, Corsale S, Amato A, Calò V, Dardanoni G, Morello V, La Farina M, Albanese I, Tomasino RM, Gebbia N, Russo A. 2002. Have p53 gene mutations and protein expression a different biological significance in colorectal cancer? J Cell Physiol 191:237-246.
4. Biramijamal F, Allameh A, Mirbod P, Groene HJ, Koomagi R, Hollstein M. 2001. Unusual profile and high prevalence of p53 mutations in esophageal squamous cell carcinomas from northern Iran. Cancer Res 61:3119-3123.
5. Bishehsari F, Mahdavinia M, Malekzadeh R, Verginelli F, Catalano T, Sotoudeh M, Bazan V, Agnese V, Esposito DL, De Lellis L, Semeraro D, Colucci G, Hormazdi M, Rakhshani N, Cama A, Piantelli M, Iacobelli S, Russo A, Mariani-Costantini R. 2006. Patterns of K-ras mutation in colorectal carcinomas from Iran and Italy (a Gruppo Oncologico dell'Italia Meridionale study): Influence of microsatellite instability status and country of origin. Ann Oncol 17:vii91-vii96.
6. Calistri D, Rengucci C, Seymour I, Lattuneddu A, Polifemo AM, Monti F, Saragoni L, Amadori D. 2005. Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression. J Cell Physiol 204:484-488.
7. Chan AO, Soliman AS, Zhang Q, Rashid A, Bedeir A, Houlihan PS, Mokhtar N, Al-Masri N, Ozbek U, Yaghan R, Kandilci A, Omar S, Kapran Y, Dizdaroglu F, Bondy ML, Amos CI, Issa JP, Levin B, Hamilton SR. 2005. Differing DNA methylation patterns and gene mutation frequencies in colorectal carcinomas from Middle Eastern countries. Clin Cancer Res 11:8281-8287.
8. Curtin K, Slattery ML, Holubkov R, Edwards S, Holden JA, Samowitz WS. 2004. p53 alterations in colon tumors: A comparison of SSCP/sequencing and immunohistochemistry. Appl Immunohistochem Mol Morphol 12:380-386.
9. Diep CB, Thorstensen L, Meling GI, Skovlund E, Rognum TO, Lothe RA. 2003. Genetic tumor markers with prognostic impact in Dukes' stages B and C colorectal cancer patients. J Clin Oncol 21:820-829.
10. Fearon ER, Vogelstein B. 1990. A genetic model for colorectal tumorigenesis. Cell 61:759-767.
11. Ferlay J, Bray F, Pisani P, Parkin DM. 2004. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide, version 2.0. IARC Cancer Base number 5. Lyon: IARC Press.
12. Frigola J, Solé X, Paz MF, Moreno V, Esteller M, Capellà G, Peinado MA. 2005. Differential DNA hypermethylation and hypomethylation signatures in colorectal cancer. Hum Mol Genet 14:319-326.
13. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. 1994. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878.
14. Hamilton SR, Aaltonen LA. 2000. World Health Organization Classification of Tumours. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press.
15. Hatch SB, Lightfoot HM, Jr., Garwacki CP, Moore DT, Calvo BF, Woosley JT, Sciarrotta J, Funkhouser WK, Farber RA. 2005. Microsatellite instability testing in colorectal carcinoma: Choice of markers affects sensitivity of detection of mismatch repair-deficient tumors. Clin Cancer Res 11:2180-2187.
16. Hayashi N, Sugai S, Ito I, Nakamori S, Ogawa M, Nakamura Y. 1996. Ethnic difference in the pattern of K-ras oncogene mutations in human colorectal cancers. Hum Mutat 8:258-261.
17. Ho JW, Yuen ST, Chung LP, Kwan KY, Chan TL, Leung SY, Chan AS, Tse C, Lam PW, Luk IS. 2000. Distinct clinical features associated with microsatellite instability in colorectal cancers of young patients. Int J Cancer 89:356-360.
18. Hosseini SV, Izadpanah A, Yarmohammadi H. 2004. Epidemiological changes in colorectal cancer in Shiraz, Iran: 1980-2000. ANZ J Surg 74:547-549.
19. Hussain SP, Harris CC. 2000. Molecular epidemiology and carcinogenesis: Endogenous and exogenous carcinogens. Mutat Res 462:311-322.
20. Iacopetta B. 2002. Are there two sides to colorectal cancer? Int J Cancer 101:403-408.
21. Iacopetta B. 2003. TP53 mutation in colorectal cancer. Hum Mutat 21:271-276.
22. Kamangar F, Dores GM, Anderson WF. 2006. Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137-2150.
23. Kaserer K, Schmaus J, Bethge U, Migschitz B, Fasching S, Walch A, Herbst F, Teleky B, Wrba F. 2000. Staining patterns of p53 immunohistochemistry and their biological significance in colorectal cancer. J Pathol 190:450-456.
24. Kim GP, Colangelo LH, Wieand HS, Paik S, Kirsch IR, Wolmark N, Allegra CJ. 2007. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 25:767-772.
25. Klump B, Nehls O, Okech T, Hsieh CJ, Gaco V, Gittinger FS, Sarbia M, Borchard F, Greschniok A, Gruenagel HH, Porschen R, Gregor M. 2004. Molecular lesions in colorectal cancer: Impact on prognosis? Original data and review of the literature. Int J Colorectal Dis 19:23-42.
26. Lin X, Ramamurthi K, Mishima M, Kondo A, Howell SB. 2000. p53 interacts with the DNA mismatch repair system to modulate the cytotoxicity and mutagenicity of hydrogen peroxide. Mol Pharmacol 58:1222-1229.
27. Lleonart ME, Garcia-Foncillas J, Sanchez-Prieto R, Martin P, Moreno A, Salas C, Ramon y Cajal S. 1998. Microsatellite instability and p53 mutations in sporadic right and left colon carcinoma: Different clinical and molecular implications. Cancer 83:889-895.
28. Mahdavinia M, Bishehsari F, Ansari R, Norouzbeigi N, Khaleghinejad A, Hormazdi M, Rakhshani N, Malekzadeh R. 2005. Family history of colorectal cancer in Iran. BMC Cancer 5:112.
29. McDermott U, Longley DB, Johnston PG. 2002. Molecular and biochemical markers in colorectal cancer. Ann Oncol 13:235-245.
30. Munro AJ, Lain S, Lane DP. 2005. P53 abnormalities and outcomes in colorectal cancer: A systematic review. Br J Cancer 92:434-444.
31. Olivier M, Hussain SP, Caron de Fromentel C, Hainaut P, Harris CC. 2004. TP53 mutation spectra and load: A tool for generating hypotheses on the etiology of cancer. IARC Sci Publ 157:247-270.
32. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M. 2007. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum Mutat 28:622-629.
33. Pfeifer GP. 2006. Mutagenesis at methylated CpG sequences. Curr Top Microbiol Immunol 301:259-281.
34. Potter JD. 1999. Colorectal cancer: Molecules and populations. J Natl Cancer Inst 91:916-932.
35. Qing SH, Rao KY, Jiang HY, Wexner SD. 2003. Racial differences in the anatomical distribution of colorectal cancer: A study of differences between American and Chinese patients. World J Gastroenterol 9:721-725.
36. Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N. 2005. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: Influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 23:7518-7528.
37. Sadjadi A, Malekzadeh R, Derakhshan MH, Sepehr A, Nouraie M, Sotoudeh M, Yazdanbod A, Shokoohi B, Mashayekhi A, Arshi S, Majidpour A, Babaei M, Mosavi A, Mohagheghi MA, Alimohammadian M. 2003. Cancer occurrence in Ardabil: Results of a population-based cancer registry from Iran. Int J Cancer 107:113-118.
38. Samowitz WS, Curtin K, Ma KN, Edwards S, Schaffer D, Leppert MF, Slattery ML. 2002. Prognostic significance of p53 mutations in colon cancer at the population level. Int J Cancer 99:597-602.
39. Semnani S, Sadjadi A, Fahimi S, Nouraie M, Naeimi M, Kabir J, Fakheri H, Saadatnia H, Ghavamnasiri MR, Malekzadeh R. 2006. Declining incidence of esophageal cancer in the Turkmen Plain, eastern part of the Caspian Littoral of Iran: A retrospective cancer surveillance. Cancer Detect Prev 30:14-19.
40. Sepehr A, Tanière P, Martel-Planche G, Zia'ee AA, Rastgar-Jazii F, Yazdanbod M, Etemad-Moghadam G, Kamangar F, Saidi F, Hainaut P. 2001. Distinct pattern of TP53 mutations in squamous cell carcinoma of the esophagus in Iran. Oncogene 20:7368-7374.
41. Soong R, Robbins PD, Dix BR, Grieu F, Lim B, Knowles S, Williams KE, Turbett GR, House AK, Iacopetta BJ. 1996. Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum Pathol 27:1050-1055.
42. Soong R, Grieu F, Robbins P, Dix B, Chen D, Parsons R, House A, Iacopetta B. 1997. p53 alterations are associated with improved prognosis in distal colonic carcinomas. Clin Cancer Res 3:1405-1411.
43. Soreide K, Janssen EA, Soiland H, Korner H, Baak JP. 2006. Microsatellite instability in colorectal cancer. Br J Surg 93:395-406.
44. Soussi T, Beroud C. 2003. Significance of TP53 mutations in human cancer: A critical analysis of mutations at CpG dinucleotides. Hum Mutat 21:192-200.
45. Toft NJ, Curtis LJ, Sansom OJ, Leiten AL, Wyllie AH, te Riele H, Arends MJ, Clarke AR. 2002. Heterozygosity for p53 promotes microsatellite instability and tumourigenesis on a Msh2 deficient background. Oncogene 21:6299-6306.
46. Vikhanskaya F, Colella G, Valenti M, Parodi S, D'Incalci M, Broggini M. 1999. Cooperation between p53 and hMLH1 in a human colocarcinoma cell line in response to DNA damage. Clin Cancer Res 5:937-941.
47. Young LC, Keuling AM, Lai R, Nation PN, Tron VA, Andrew SE. 2007. The associated contributions of p53 and the DNA mismatch repair protein Msh6 to spontaneous tumorigenesis. Carcinogenesis 28:2131-2138.